Related Experiment Video
Updated: Apr 19, 2026

Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand
Gang Liu1, Cynthia Sprenger2, Pin-Jou Wu1
1Department of Medicine, University of Washington, Seattle 98104, WA, USA.
Abstract:
The appearance of constitutively active androgen receptor splice variants (AR-Vs) has been proposed as one of the causes of castration-resistant prostate cancer (CRPC). However, the underlying mechanism of AR-Vs in CRPC transcriptional regulation has not been defined. A distinct transcriptome enriched with cell cycle genes, e.g. UBE2C, has been associated with AR-Vs, which indicates the possibility of an altered transcriptional mechanism when compared to full-length wild-type AR (ARfl). Importantly, a recent study reported the critical role of p-MED1 in enhancing UBE2C expression through a locus looping pattern, which only occurs in CRPC but not in androgen-dependent prostate cancer (ADPC). To investigate the potential correlation between AR-V and MED1, in the present study we performed protein co-immunoprecipitation, chromatin immunoprecipitation, and cell proliferation assays and found that MED1 is necessary for ARv567es induced UBE2C up-regulation and subsequent prostate cancer cell growth. Furthermore, p-MED1 is bound to ARv567es independent of full-length AR; p-MED1 has higher recruitment to UBE2C promoter and enhancer regions in the presence of ARv567es. Our data indicate that p-MED1 serves as a key mediator in ARv567es induced gene expression and suggests a mechanism by which AR-Vs promote the development and progression of CRPC.
Insights
Constitutively active androgen receptor splice variants (AR-Vs) drive castration-resistant prostate cancer (CRPC) by upregulating UBE2C. MED1 is essential for this AR-V-mediated gene expression and prostate cancer cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Constitutively active androgen receptor splice variants (AR-Vs) are implicated in castration-resistant prostate cancer (CRPC) development.
- The precise mechanisms of AR-Vs in CRPC transcriptional regulation remain unclear.
- AR-V-associated transcriptomes show enrichment in cell cycle genes like UBE2C, suggesting altered transcriptional control compared to full-length AR (ARfl).
Purpose of the Study:
- To investigate the correlation between androgen receptor splice variants (AR-Vs) and MED1 in CRPC.
- To elucidate the role of MED1 in AR-V-mediated UBE2C expression and prostate cancer cell proliferation.
Main Methods:
- Protein co-immunoprecipitation assays.
- Chromatin immunoprecipitation assays.
- Cell proliferation assays.
Main Results:
- MED1 is crucial for ARv567es-induced UBE2C upregulation and subsequent prostate cancer cell growth.
- Phosphorylated MED1 (p-MED1) binds to ARv567es independently of ARfl.
- p-MED1 exhibits enhanced recruitment to UBE2C promoter and enhancer regions in the presence of ARv567es.
Conclusions:
- p-MED1 acts as a key mediator in ARv567es-driven gene expression.
- This study suggests a mechanism by which AR-Vs promote CRPC development and progression through p-MED1 and UBE2C.
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
Master Transcription Regulators
Master Transcription Regulators

